Mario Gössl1, Robert S Farivar2, Richard Bae2, Paul Sorajja2. 1. Valve Science Center, Minneapolis Heart Institute Abbott Northwestern Hospital, part of Allina Health, 920 East 28th Street, Suite 300, Minneapolis, MN, 55407, USA. mario.goessl@allina.com. 2. Valve Science Center, Minneapolis Heart Institute Abbott Northwestern Hospital, part of Allina Health, 920 East 28th Street, Suite 300, Minneapolis, MN, 55407, USA.
Abstract
PURPOSE OF REVIEW: This review examines the current status of catheter-based repair and replacement for mitral valve disease, with a focus on native primary and secondary mitral valve regurgitation. RECENT FINDINGS: Transcatheter mitral valve repair with the MitraClip®, with >40,000 performed procedures worldwide, has significantly advanced the field of transcatheter therapy for mitral valve regurgitation. Transcatheter mitral valve replacement remains in the early stages of development, mainly due to the complex anatomy and physiology of the mitral valve. Early feasibility studies in high-risk patients show promising procedural success, yet the adverse events require further study. Transcatheter therapies for mitral valve disease are the next endeavor for the pioneers of percutaneous structural heart disease interventions. Early results are encouraging but also show that further rigorous study is needed to determine efficacy and safety.
PURPOSE OF REVIEW: This review examines the current status of catheter-based repair and replacement for mitral valve disease, with a focus on native primary and secondary mitral valve regurgitation. RECENT FINDINGS: Transcatheter mitral valve repair with the MitraClip®, with >40,000 performed procedures worldwide, has significantly advanced the field of transcatheter therapy for mitral valve regurgitation. Transcatheter mitral valve replacement remains in the early stages of development, mainly due to the complex anatomy and physiology of the mitral valve. Early feasibility studies in high-risk patients show promising procedural success, yet the adverse events require further study. Transcatheter therapies for mitral valve disease are the next endeavor for the pioneers of percutaneous structural heart disease interventions. Early results are encouraging but also show that further rigorous study is needed to determine efficacy and safety.
Authors: Philipp Blanke; Christopher Naoum; Danny Dvir; Vinayak Bapat; Kevin Ong; David Muller; Anson Cheung; Jian Ye; James K Min; Nicolo Piazza; Pascal Theriault-Lauzier; John Webb; Jonathon Leipsic Journal: JACC Cardiovasc Imaging Date: 2016-03-09
Authors: Hunaid A Vohra; Robert N Whistance; Apostolos Roubelakis; Andrew Burton; Clifford W Barlow; Geoffrey M K Tsang; Steve A Livesey; Sunil K Ohri Journal: Interact Cardiovasc Thorac Surg Date: 2012-01-31
Authors: Vinay Badhwar; Eric D Peterson; Jeffrey P Jacobs; Xia He; J Matthew Brennan; Sean M O'Brien; Rachel S Dokholyan; Kristopher M George; Steven F Bolling; David M Shahian; Fredrick L Grover; Fred H Edwards; James S Gammie Journal: Ann Thorac Surg Date: 2012-08-02 Impact factor: 4.330
Authors: Daniel Goldstein; Alan J Moskowitz; Annetine C Gelijns; Gorav Ailawadi; Michael K Parides; Louis P Perrault; Judy W Hung; Pierre Voisine; Francois Dagenais; A Marc Gillinov; Vinod Thourani; Michael Argenziano; James S Gammie; Michael Mack; Philippe Demers; Pavan Atluri; Eric A Rose; Karen O'Sullivan; Deborah L Williams; Emilia Bagiella; Robert E Michler; Richard D Weisel; Marissa A Miller; Nancy L Geller; Wendy C Taddei-Peters; Peter K Smith; Ellen Moquete; Jessica R Overbey; Irving L Kron; Patrick T O'Gara; Michael A Acker Journal: N Engl J Med Date: 2015-11-09 Impact factor: 91.245